Source: MarketScreener

Salix Pharmaceuticals: New Data on Cost Impact of Treating Opioid-Induced Constipation (OIC) with FDA-Approved Medications, Including Salix's RELISTOR Subcutaneous Injection (Methylnaltrexone Bromide), in The Emergency Department Is Published in Advances In Therapy

(marketscreener.com) Research Reveals Reduction in Hospitalization Rates, Length of Stay and Health Care Costs When Treating OIC with FDA-Approved Prescription Medications LAVAL, QC, March 24, 2022 /PRNewswire/ -- Bausch Health Companies Inc. "Bausch Health" and its gastroenterology business, Salix Pharmaceuticals , one of the largest specialty pharmaceutical...https://www.marketscreener.com/quote/stock/BAUSCH-HEALTH-COMPANIES-I-44965076/news/New-Data-on-Cost-Impact-of-Treating-Opioid-Induced-Constipation-OIC-with-FDA-Approved-Medications-39849023/?utm_medium=RSS&utm_content=20220324

Read full article »
Est. Annual Revenue
$1.0-5.0B
Agree?
Est. Employees
500-1.0K
Agree?
Robert Spurr's photo - President of Salix Pharmaceuticals

President

Robert Spurr

CEO Approval Rating

82/100

Read more